Glenmark and Torrent sign a license agreement to market diabetes drugs

MUMBAI: Glenmark and Torrent Pharma announced that they have signed a non-exclusive sub-license agreement to jointly market the anti-diabetes medication, the sodium glucose co-transporter-2 inhibitor (SGLT2). Remobififlozin Etabonate (Remogliflozin) in India.

Under the terms of the agreement, Glenmark will receive an upfront payment, license fees and royalties from Torrent. Glenmark will manufacture and supply Remogliflozin, while Torrent will market the drug under its own trademark 'Zucator', says a company statement.

This agreement is an effort to widen access to the latest drug, Remobififlozin Etabonate , indicated for treatment of Type 2 diabetes in India.In April 2019, Glenmark received approval from the Drugs Controller General of India for Remobififlozin Etabonate after successfully completing Phase-3 clinical trials, and subsequently, launched it under the brand names ‘Remo’ and ‘Remozen’.

Remogliflozin is available at a lower price than other SGLT-2 inhibitors available in the country, he adds.